ASCO GU 2020 Kidney Cancer

Viewing 1-20 of 57 articles

ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Surgeon’s Perspective

ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Pathologists Perspective

ASCO GU 2020: Comparing Nivolumab versus Everolimus with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma: A Final Analysis of the CheckMate 025 Trial

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma - From the Perspective of a Radiologist

ASCO GU 2020: The Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

ASCO GU 2020: A Phase I/II Study of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cancer that Progressed on Prior Anti-Angiogenic Therapy

ASCO GU 2020: Overall Survival Results for Durvalumab and Savolitinib in Metastatic Papillary Renal Cancer — CALYPSO trial

ASCO GU 2020: Novel Drugs for Clear Cell Renal Cell Carcinoma

ASCO GU 2020: Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Genomic Findings

ASCO GU 2020: Evaluation of RNA-Sequencing Signatures with Pembrolizumab in Patients with Renal Cell Carcinoma from KEYNOTE-427 Cohort A

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Neoadjuvant Therapy for Localized RCC

ASCO GU 2020: Nonsurgical Local Treatment Options and Their Limits: Stereotactic Radiation

ASCO GU 2020: Nonsurgical Local Treatment Options and Their Limits: Percutaneous Ablation

ASCO GU 2020: Depth of Response (DepOR) Analysis and Correlation with Clinical Outcomes from JAVELIN Renal 101

ASCO GU 2020: Molecular Characteristics of Renal Cell Carcinoma Risk Groups from JAVELIN Renal 101

ASCO GU 2020: Evaluation of Brain Metastasis in JAVELIN Renal 101: Efficacy of Avelumab + Axitinib versus Sunitinib

ASCO GU 2020: (NIVOSWITCH) - Switch to Nivolumab with TKI Continuation After 12 Weeks of TKI Induction Therapy in Metastatic Renal Cell Carcinoma

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Rechallenge with ICI Following Immune-Related Adverse Events

ASCO GU 2020: Emerging therapies in Renal Cell Carcinoma: From PARP Inhibition to Novel Immunotherapy Agents

1
2
3